Home / Article

BFCH to Acquire EVERMIND™ Beverage, Strengthening Cognitive Health Portfolio

Burstable News - Business and Technology News August 4, 2025
By Burstable News Staff
Read Original Article →
BFCH to Acquire EVERMIND™ Beverage, Strengthening Cognitive Health Portfolio

Summary

BitFrontier Capital Holdings, Inc. (BFCH) announces the acquisition of EVERMIND™, a science-backed cognitive health beverage platform, marking a strategic move to enhance its wellness ecosystem and balance sheet.

Full Article

BitFrontier Capital Holdings, Inc. (OTC: BFCH), operating as EVERMIND Holdings, Inc., has entered into a binding Letter of Intent (LOI) to acquire ERApeutics, LLC, the creator of the EVERMIND™ beverage platform. This acquisition, valued at $4,000,000 through the issuance of 400,000,000 restricted common shares at $0.01 per share, signifies BFCH's commitment to expanding its footprint in the cognitive health and wellness sector. EVERMIND™, a physician-formulated, plant-based protein shake, is designed to support brain health with both immediate and long-term benefits, backed by scientific research and ready for commercial launch.

The EVERMIND™ platform includes six proprietary nootropic and adaptogenic formulations, alongside a robust R&D pipeline, academic research, and registered trademarks. With a fully integrated e-commerce system via thinkevermind.com, the brand is poised for rapid market entry. The acquisition not only adds significant intellectual property and assets to BFCH's portfolio but also aligns with the company's strategy to uplist to the OTCQB market, following the elimination of over $2 million in toxic convertible debt and reducing total liabilities to under $94,000.

Dr. Jordan Balencic, CEO of BFCH, emphasized the strategic importance of EVERMIND™, comparing its potential impact on cognitive health to that of Celsius in the metabolic health space. The functional beverage market, witnessing significant investments from major players like Keurig Dr Pepper and Coca-Cola, presents a lucrative opportunity for BFCH to capitalize on the growing demand for wellness-oriented products. The transaction, expected to close within 60 to 90 days, will see EVERMIND™ operating as a wholly owned subsidiary of EVERMIND Labs, with potential for future spin-offs.

This move by BFCH underscores the increasing institutional interest in the functional beverage sector, particularly those offerings that combine health benefits with consumer convenience. EVERMIND™'s focus on cognitive performance, mood, and mental clarity positions it uniquely within this competitive landscape, offering a scalable and scientifically validated product that meets the evolving needs of health-conscious consumers.

QR Code for Content Provenance

This story is based on an article that was registered on the blockchain. The original source content used for this article is located at NewMediaWire

Article Control ID: 134070